GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Operating Margin %

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ampio Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-2.22 Mil. Ampio Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Ampio Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Ampio Pharmaceuticals's Operating Margin % or its related term are showing as below:


AMPE's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -161.26
* Ranked among companies with meaningful Operating Margin % only.

Ampio Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ampio Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-2.22 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.52 Mil.


Ampio Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Ampio Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals Operating Margin % Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ampio Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Ampio Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's Operating Margin % falls into.



Ampio Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ampio Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-9.518 / 0
= %

Ampio Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.215 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ampio Pharmaceuticals  (OTCPK:AMPE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ampio Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Michael A Martino director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes director 640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka officer: Chief Operating Officer C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely officer: CFO 4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow officer: Chief Operating Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso director C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles director 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or director, officer: Chief Scientific Officer C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift officer: Chief Regulatory Affairs 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor officer: Chief Financial Officer 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111